Targeted RNA nanoparticle shows early promise as liver cancer treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A targeted RNA nanoparticle designed to carry a chemotherapy drug along with a therapeutic oligonucleotide against chemical efflux gene might provide an effective treatment for liver cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The study, published in the Journal of Controlled Release, shows that the RNA nanoparticles efficiently target hepatocellular carcinoma cells and are stable, safe, and effective both in laboratory and animal studies. The findings suggest that the nanoparticles could offer an effective new treatment for HCC.

The RNA nanoparticles carry paclitaxel and display molecules that target HCC cells. They also contain a microRNA that inactivates a chemical efflux pump called p-glycoprotein, which usually pumps out chemotherapeutic drugs from the liver cells, making cancer untreatable.

“Liver cells express drug exporter pumps that are used to remove chemotherapeutic drugs and detoxify the body. This renders the treatment with chemical drugs ineffective, and contributes to drug resistance,” study leader and corresponding author Peixuan Guo, professor at Ohio State’s College of Pharmacy and the Sylvan G. Frank Endowed Chair in Pharmaceutics and Drug Delivery, said in a statement. Guo also is a member of the OSUCCC – James Translational Therapeutics Program. “This could be why liver cancer responds poorly to chemotherapy treatment.”

Earlier work by Guo and his team showed that RNA nanoparticles have rubbery or amoeba-like properties that enable them to stretch, shrink then return to their normal shape.

“We believe that this amoeba and rubber-like property enables RNA nanoparticles to slip through the poorly formed walls of tumor blood vessels and enter the tumor mass,” said Guo, who directs Ohio State’s Center for RNA Nanobiotechnology and Nanomedicine.

“This same rubbery property could allow the kidneys to filter RNA nanoparticles from the blood and excrete them in the urine, thereby eliminating them from the body swiftly,” said Guo. “This, in turn, could reduce retention of anticancer RNA nanoparticles in vital organs, lowering the drug’s toxicity.”

For this study, Guo and his colleagues constructed the RNA nanoparticles using six RNA strands that self-assembled into a globular structure. The nanoparticle served as a cargo system to deliver both Paclitaxel and microRNA (miR122) along with HCC targeting ligands. They conjugated 24 molecules of paclitaxel, along with HCC targeting molecules (a derivative of galactosamine) and one microRNA to the multivalent RNA nanoparticle. The sequence for the microRNA extends from one of the RNA strands. The final structure is about 18 nanometers in size.

The study’s key findings include:

  • RNA nanoparticles selectively bind and deliver therapeutic agents into liver cancer cells efficiently.

  • The attached miR122 effectively inhibits the liver drug-efflux pump.

  • RNA nanoparticles carrying both Paclitaxel and miR122 more effectively inhibited tumor growth compared to Paclitaxel or miR122 alone; nanoparticles without treatment groups showed no cancer-cell inhibition effects.

  • Animal studies showed that the RNA nanoparticle formulation targeted tumor cells effectively and strongly inhibited tumor growth due to the synergistic effect of Paclitaxel and miR122, without affecting healthy organs.

In This Issue

YOU MAY BE INTERESTED IN

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...